Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Robert S, Seitz"'
Autor:
David B. Page, Joanna Pucilowska, Brie Chun, Isaac Kim, Katherine Sanchez, Nicole Moxon, Staci Mellinger, Yaping Wu, Yoshinobu Koguchi, Valerie Conrad, William L. Redmond, Maritza Martel, Zhaoyu Sun, Mary B. Campbell, Alison Conlin, Anupama Acheson, Reva Basho, Philomena McAndrew, Mary El-Masry, Dorothy Park, Laura Bennetts, Robert S. Seitz, Tyler J. Nielsen, Kimberly McGregor, Venkatesh Rajamanickam, Brady Bernard, Walter J. Urba, Heather L. McArthur
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-13 (2023)
Abstract Chemoimmunotherapy with anti-programmed cell death 1/ligand 1 and cytotoxic chemotherapy is a promising therapeutic modality for women with triple-negative breast cancer, but questions remain regarding optimal chemotherapy backbone and bioma
Externí odkaz:
https://doaj.org/article/0206d7fb11584f5ab468ac8a9e5bed64
Autor:
Robert S. Seitz, Michael E. Hurwitz, Tyler J. Nielsen, Daniel B. Bailey, Matthew G. Varga, Brian Z. Ring, Carrie F. Metts, Brock L. Schweitzer, Kimberly McGregor, Douglas T. Ross
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-11 (2022)
Abstract Background The IO Score is a 27-gene immuno-oncology (IO) classifier that has previously predicted benefit to immune checkpoint inhibitor (ICI) therapy in triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC). It genera
Externí odkaz:
https://doaj.org/article/559b3f8416ed47f4ba8dbc1a517b7989
Autor:
Harsha Ranganath, Amit L. Jain, Justin R. Smith, Julie Ryder, Amina Chaudry, Emily Miller, Felicia Hare, Poojitha Valasareddy, Robert S. Seitz, David R. Hout, Matthew G. Varga, Brock L. Schweitzer, Tyler J. Nielsen, Janice Mullins, Douglas T. Ross, David R. Gandara, Gregory A. Vidal
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Immune checkpoint inhibitor (ICI) therapies represent a major advance in treating a variety of advanced-stage malignancies. Nevertheless, only a subset of patients benefit, even when selected based on approved biomarkers such as P
Externí odkaz:
https://doaj.org/article/ca410bdf72ce41f5b615b14aab591ed1
Autor:
David L. Saltman, Tyler J. Nielsen, Davide Salina, David R. Hout, Frank B. McMahon, Boris R. Valev, Michael Huk, Pranil K. Chandra, Jeremy Spille, Robert S. Seitz, Brock L. Schweitzer
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Single-agent immune checkpoint inhibitor therapy in advanced non-small cell lung cancer can significantly prolong progression-free and overall survival when compared with cytotoxic chemotherapy. Here, we report a case of newly diagnosed adenocarcinom
Externí odkaz:
https://doaj.org/article/7b2d91b2251644438a237f9b577cb0d2
Publikováno v:
Heliyon, Vol 7, Iss 3, Pp e06438- (2021)
Immune checkpoint inhibitor (ICI) therapies can improve clinical outcomes for patients with solid tumors, but relatively few patients respond. Because ICI therapies support an adaptive immune response, patients with an active tumor microenvironment (
Externí odkaz:
https://doaj.org/article/58ad701311c34bcc966073d484c3d0d5
Autor:
Bojana Jovanović, Quanhu Sheng, Robert S. Seitz, Kasey D. Lawrence, Stephan W. Morris, Lance R. Thomas, David R. Hout, Brock L. Schweitzer, Yan Guo, Jennifer A. Pietenpol, Brian D. Lehmann
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-14 (2017)
Abstract Background Triple negative breast cancer (TNBC) is a heterogeneous disease that lacks unifying molecular alterations that can guide therapy decisions. We previously identified distinct molecular subtypes of TNBC (TNBCtype) using gene express
Externí odkaz:
https://doaj.org/article/0dd8174f05f648f7b930cfdb70942ede
Autor:
Warner K. Huh, Neville F. Hacker, Philippa M. O'Brien, Robert L. Sutherland, Robert S. Seitz, Doug T. Ross, Brian Z. Ring, Goli Samimi
PDF file - 18K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::640a83e33c2370b9bfebf0c87c763fc1
https://doi.org/10.1158/1055-9965.22436356
https://doi.org/10.1158/1055-9965.22436356
Autor:
Warner K. Huh, Neville F. Hacker, Philippa M. O'Brien, Robert L. Sutherland, Robert S. Seitz, Doug T. Ross, Brian Z. Ring, Goli Samimi
Background: We have previously shown that transducin-like enhancer of split 3 (TLE3) is associated with outcome specifically in patients with taxane-treated breast cancer and not in patients treated with anthracycline-based regimens without a taxane.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9235514197c1eb541c1efc2d97736565
https://doi.org/10.1158/1055-9965.c.6515362.v1
https://doi.org/10.1158/1055-9965.c.6515362.v1
Autor:
Matteo Dugo, Chiun-Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Robert S. Seitz, Tyler J. Nielsen, Marc Thill, Antonio Anton, Stefania Russo, Eva Maria Ciruelos, Brock L. Schweitzer, Douglas T. Ross, Barbara Galbardi, Richard Greil, Vladimir Semiglazov, Balázs Gyorffy, Marco Colleoni, Catherine Kelly, Gabriella Mariani, Lucia Del Mastro, Pinuccia Valagussa, Giuseppe Viale, Maurizio Callari, Luca Gianni, Giampaolo Bianchini
Publikováno v:
Cancer Research. 82:PD10-06
Background The identification of biomarkers for optimization of immune checkpoint inhibitors (ICI) treatment is an unmet clinical need. In the Phase III randomized trial, NeoTRIPaPDL1, a post-hoc analysis of whole transcriptome RNA-Seq data, previous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ba2e86f1336cac9a2bc267a760706f2
https://doi.org/10.1158/1538-7445.sabcs21-pd10-06
https://doi.org/10.1158/1538-7445.sabcs21-pd10-06
Autor:
Matteo Dugo, Chiun-Sheng Huang, Daniel Egle, Begoña Bermejo, Claudio Zamagni, Robert S. Seitz, Tyler J. Nielsen, Marc Thill, Antonio Anton, Stefania Russo, Eva Maria Ciruelos, Brock L. Schweitzer, Douglas T. Ross, Barbara Galbardi, Richard Greil, Vladimir Semiglazov, Balázs Gyorffy, Marco Colleoni, Catherine Kelly, Gabriella Mariani, Lucia Del Mastro, Pinuccia Valagussa, Giuseppe Viale, Maurizio Callari, Luca Gianni, Giampaolo Bianchini
Publikováno v:
Cancer Research. 82:P2-07
Background A post-hoc of NeoTRIP trial showed that 27-gene IO score assessed on baseline samples is predictive of increased pathological complete response (pCR) with the addition of atezolizumab to carboplatin/nab-paclitaxel, whereas the LAR subtype
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4c4f5836c35e6a39bd1d6ed7db080f4
https://doi.org/10.1158/1538-7445.sabcs21-p2-07-12
https://doi.org/10.1158/1538-7445.sabcs21-p2-07-12